LITS

#4383
Lite Strategy, Inc. - Common Stock
1.0 5 USD
+0.06%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
1.04
1.06
Jahresspanne
0.69
3.23
Tagesänderung
+6.06%
Monatliche Änderung
+8.25%
6 month change
-4.55%
Jahresänderung
-64.77%
Vorheriger Schlusskurs
0.9 9
Open
1.0 5
Tief
1.0 4
Hoch
1.0 6
Volumen
13
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Lite Strategy, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Lite Strategy, Inc. current report, Q3 FY2026
8-K
Current report, Q2 FY2026
Lite Strategy, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q3 FY2026
Lite Strategy, Inc. quarterly report, Q3 FY2026
10-Q
Current report, Q1 FY2026
Lite Strategy, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Lite Strategy, Inc. current report, Q1 FY2026
8-K

2025

Quarterly report, Q2 FY2025
Lite Strategy, Inc. quarterly report, Q2 FY2025
10-Q
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K

Lite Strategy, Inc. current report, 22 February 2023

Full document

SEC Filing Summary: MEI Pharma, Inc. (Form 8-K)

Business Context and Reporting Period

Date: February 22, 2023
Company: MEI Pharma, Inc. (Nasdaq: MEIP)
Event: Entry into a Material Definitive Agreement (Agreement and Plan of Merger) with Infinity Pharmaceuticals, Inc. ("Infinity").
Structure: MEI Pharma will acquire Infinity via a merger with a wholly-owned subsidiary. Infinity will become a wholly-owned subsidiary of MEI Pharma. The transaction is structured as a tax-free reorganization under Section 368(a) of the Internal Revenue Code.

Key Financial Metrics and Transaction Terms

Exchange Ratio: 1.0449 shares of MEI Pharma common stock for each share of Infinity common stock.
Ownership Post-Closing: MEI Pharma stockholders will own approximately 58% of the combined company; Infinity stockholders will own approximately 42%.
Termination Fees:

  • MEI Pharma to pay Infinity: $4,000,000 under specified termination circumstances.
  • Infinity to pay MEI Pharma: $2,900,000 under specified termination circumstances.
Expense Reimbursement: Up to $1,000,000 payable to the non-terminating party upon termination under specified circumstances.
Financial Data: The filing text does not provide specific revenue, profit, cash flow, or debt figures for either company. Investors are directed to the Joint Proxy Statement/Prospectus for detailed financial information.

Material Changes and Governance

Executive Leadership Changes (Effective Prior to Closing):

  • Resignation: Daniel Gold, Ph.D., will resign as Chief Executive Officer (CEO) but will remain on the Board of Directors.
  • Appointment: David M. Urso (current COO and General Counsel) will become CEO.
Board of Directors Changes (Effective Post-Closing):
  • Resignations: Tamar D. Howson, Nicholas R. Glover, and Frederick W. Driscoll will resign from the MEI Pharma Board.
  • Appointments: Norman C. Selby, Adelene Q. Perkins, and Richard Gaynor, M.D. (current Infinity board members) will be appointed to the combined company's Board.
Scientific Leadership (Effective Post-Closing):
  • Robert Ilaria Jr., M.D., will become Chief Medical Officer.
  • Stéphane Peluso, Ph.D., will become Chief Scientific Officer.
Bylaws Amendment: The Company adopted Fifth Amended and Restated Bylaws to comply with SEC Universal Proxy Rules and update forum selection provisions.

Guidance, Outlook, and Risks

Closing Timeline: Expected to occur in mid-2023.
Conditions to Closing:

  • Effectiveness of the Form S-4 Registration Statement.
  • Stockholder approval from both MEI Pharma and Infinity.
  • Absence of laws or judgments prohibiting the merger.
  • Continued listing of MEI Pharma stock on Nasdaq.
  • No "material adverse effect" on either party.
  • Minimum Net Cash requirements met by both parties at Closing.
Key Risks and Contingencies:
  • Failure to obtain stockholder or regulatory approvals.
  • Termination of the agreement due to breach, change of recommendation, or failure to close by August 31, 2023.
  • Disruption of business operations and retention of key personnel during the pendency of the merger.
  • Uncertainties regarding the clinical development and regulatory approval of product candidates (specifically Infinity's eganelisib).
  • Integration risks and potential failure to realize anticipated synergies.
Management Commentary: The merger is intended to combine MEI Pharma's capabilities with Infinity's oncology pipeline. The filing includes a cautionary statement regarding forward-looking statements, noting that actual results may differ materially from expectations.

Investor Verification Checklist

  • Joint Proxy Statement/Prospectus: Verify the full financial details, pro forma capitalization, and specific terms of the merger once filed with the SEC.
  • Stockholder Approval: Confirm the dates and outcomes of the special stockholder meetings for both MEI Pharma and Infinity.
  • Cash Position: Review the "Minimum Net Cash" requirements and current liquidity positions of both entities to assess closing viability.
  • Regulatory Status: Monitor the status of the Form S-4 filing and any potential regulatory reviews or stop orders.
  • Termination Triggers: Review the specific conditions under which the $4.0M or $2.9M termination fees would be triggered.